# Bita Sehat

> Bita Sehat is a Series B investor at Industrifonden backing Health Care and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Industrifonden](https://shizune.co/investors/profile/industrifonden)
- Total investments: 4
- Last investment: Oct 2023
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bitasehat/

Bita Sehat is a Series B investor at Industrifonden focused on Health Care and Medical. Bita Sehat is the Investment Manager of Life Science at Industrifonden.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Medical | 1 | 25% |
| Wellness | 1 | 25% |
| Life Science | 1 | 25% |
| Biotechnology | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 25% |
| Series C | 1 | 25% |
| Funding Round | 1 | 25% |
| Venture - Series Unknown | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 1 | 25% |
| Denmark | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M |  | Oct 11, 2023 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M | Series C | Dec 15, 2022 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $52M | Series B | Dec 15, 2020 |  |
| Gesynta Pharma | Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $20.5M | Venture - Series Unknown | Jul 07, 2020 |  |

4 of 4 investments shown.

## Co-investors
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 3 deals together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 3 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 3 deals together
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 3 deals together
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 2 deals together
- [LF Investment](https://shizune.co/investors/profile/lf-investment) — VC Fund, 2 deals together

## About Industrifonden

VC Fund · Stockholm, Sweden

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

5 contacts available at Industrifonden.

| Name | Title | Profile |
| --- | --- | --- |
| Anna Ljungdahl | Investment Manager | https://shizune.co/investors/profile/anna-ljungdahl |
| Bita Sehat | Investment Manager of Life Science | https://shizune.co/investors/profile/bita-sehat |
| Hadar Cars | Senior Investment Director | https://shizune.co/investors/profile/hadar-cars |
| Hansson Lennart | Business Unit Manager Life Science | https://shizune.co/investors/profile/hansson-lennart |
| Jonas Brambeck | Investment Manager - Life Science | https://shizune.co/investors/profile/jonas-brambeck |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Bita Sehat invest in?

Bita Sehat invests primarily in Health Care, Medical and Wellness startups, most often at Series B and Series C stage. Most of the 4 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bita Sehat last invest?

The most recent investment recorded for Bita Sehat closed in Oct 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co